Sino Biopharm presents phase III data and 23 analysts cover Sino Biopharm stock

Published on 10/25/2026 at 02:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

First-half revenue reached CNY 19.44 billion versus CNY 17.57 billion. Sino Biopharm stock was last at HKD 5.00 on October 23, 2026 in Hong Kong.

Clinical pipeline evidence

TQB2102 reduced the risk of progression or death by 71 percent in a phase III study on October 23, 2026.
First-half revenue reached CNY 19.44 billion versus CNY 17.57 billion a year earlier.
Sino Biopharm stock was last at HKD 5.00 on October 23, 2026 at 4:08 p.m. HKT.

Sino Biopharm, KYG8167W1380, Illustration mit AI erstellt.

Sino Biopharm presented phase III TQB2102 data on October 23, 2026, while 23 analysts covered Sino Biopharm stock, according to MarketScreener. The data put the company's oncology pipeline at the center of its investment case.

Phase III data sharpen the pipeline

The APEX-Breast01 study tested TQB2102 in HER2-low advanced breast cancer. Median progression-free survival reached 16.4 months with TQB2102 versus 5.5 months with chemotherapy, reducing the risk of progression or death by 71 percent, MarketScreener reported on October 23, 2026. The study randomized 543 patients, including 269 to TQB2102 and 274 to chemotherapy.

Three events show pipeline pace

On September 11, 2026, Sino Biopharmaceutical agreed to acquire an additional 5 percent stake in Chia Tai-Tianqing Pharmaceutical Holdings for CNY 4.48 billion, according to MarketScreener. On October 20, 2026, its subsidiary completed enrollment in a phase III nasal polyp trial, with the same source reporting the event. On October 23, 2026, the TQB2102 results supplied the latest clinical milestone, again reported by MarketScreener.

What does the data mean for risk?

The efficacy signal came with measurable safety information. TQB2102 produced an objective response rate of 68.8 percent versus 31.0 percent for chemotherapy, while treatment-related interstitial lung disease occurred in 2.2 percent of patients and grade 3 cases in 1.1 percent, according to MarketScreener. For investors, the comparison with chemotherapy matters because the clinical advantage must ultimately support regulatory and commercial progress.

Reporting dates add checkpoints

Barrons lists November 30, 2026, for fourth-quarter 2026 earnings and April 1, 2027, for fiscal-year 2026 earnings. Those dates give the market two formal checkpoints for judging whether the development pipeline is translating into financial momentum.

Hong Kong quote stays in view

First-half 2026 revenue reached CNY 19.44 billion versus CNY 17.57 billion a year earlier, according to The Wall Street Journal. Sino Biopharm stock was last at HKD 5.00 on October 23, 2026 at 4:08 p.m. HKT on the Hong Kong Stock Exchange. The company had a market capitalization of HKD 89.0 billion and a 52-week range of HKD 4.19 to HKD 7.48 on that date. The listing and ticker 1177 are identified by Goodinvest.